DEUTSCHE BANK AG\
BankPosition in SLS — SELLAS Life Sciences Group, Inc.
CIK 948046
FRANKFURT AM MAIN, 2M
Position in SLS
as of Jun 30, 2026
· filed Aug 7, 2026
Position Value
$2,806,288
+$2,224,047 QoQ
Shares Held
190,128
+38.1% QoQ
Ownership
0.094%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#37
of 192 holders
Holding Since
Jun 2025
5 quarters on record
Voting authority
Sole 2%
Shared 0%
None 98%
Common Shares in SLS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026DEUTSCHE BANK AG\ holds $3,199,137,357 across 296 Biotechnology names. SLS ranks #93 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
1,579,110 | $784,391,303 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
518,409 | $323,248,743 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
815,400 | $245,459,858 | |
| 4 | RVMD |
Revolution Medicines, Inc.
|
888,019 | $166,308,196 | |
| 5 | RPRX |
Royalty Pharma plc
|
2,717,951 | $152,395,510 | |
| 6 | INCY |
Incyte Corp
|
1,262,988 | $143,172,312 | |
| 7 | ARGX |
Argenx SE
|
137,335 | $127,415,291 | |
| 8 | LGND |
Ligand Pharmaceuticals Inc
|
249,611 | $78,899,539 |
All Filings in SLS
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2,806,288 | 190,128 | Shares | Defined | 2026-08-07 | |
| 2026-03-31 | $582,241 | 137,646 | Shares | Defined | 2026-05-06 | |
| 2025-12-31 | $345,662 | 91,688 | Shares | Defined | 2026-02-11 | |
| 2025-09-30 | $194,849 | 121,025 | Shares | Defined | 2025-11-13 | |
| 2025-06-30 | $5,113 | 2,335 | Shares | Defined | 2025-08-12 | |
| No filing history on record for this holder in this stock. | ||||||